Literature DB >> 21924674

Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

Ajay R Bharti1, Scott L Letendre, Tanya Wolfson, David Clifford, Ann C Collier, Benjamin Gelman, Justin McArthur, Christina Marra, Allen McCutchan, Susan Morgello, David Simpson, Ron J Ellis, Igor Grant.   

Abstract

BACKGROUND: A substantial number of people living with HIV (PLWH) are co-infected with Hepatitis C Virus (HCV) but have a negative screening HCV antibody test (seronegative HCV infection, or SN-HCV).
OBJECTIVE: To identify a concise set of clinical variables that could be used to improve case finding for SN-HCV co-infection among PLWH. STUDY
DESIGN: Two hundred HIV-infected participants of the CHARTER study were selected based on 7 clinical variables associated with HCV infection but were HCV seronegative. Data were analyzed using Fisher's exact tests, receiver-operating characteristic (ROC) curves, and logistic regression.
RESULTS: Twenty-six (13%) participants had detectable HCV RNA. SN-HCV was associated with a history of IDU, elevated ALT and AST, low platelets, black ethnicity, and undetectable HIV RNA in plasma. Each of these clinical variables, except for abnormal AST, remained independently associated with SN-HCV in a multivariate logistic regression analysis. A composite risk score correctly identified SN-HCV with sensitivity up to 85% and specificity up to 88%.
CONCLUSIONS: In a substantial minority of PLWH, seronegative HCV viremia can be predicted by a small number of clinical variables. These findings, after validation in an unselected cohort, could help focus screening in those at highest risk.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924674      PMCID: PMC3217127          DOI: 10.1016/j.jcv.2011.08.021

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  22 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

2.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  HIV Clin Trials       Date:  2001 Nov-Dec

3.  Peripheral blood count abnormalities among patients with hepatitis C in the United States.

Authors:  Michael B Streiff; Shruti Mehta; David L Thomas
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

4.  Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.

Authors:  J Grebely; J D Raffa; C Lai; T Kerr; B Fischer; M Krajden; G J Dore; M W Tyndall
Journal:  J Viral Hepat       Date:  2011-01       Impact factor: 3.728

5.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

6.  Hepatitis C virus infection in San Francisco's HIV-infected urban poor.

Authors:  Christopher S Hall; Edwin D Charlebois; Judith A Hahn; Andrew R Moss; David R Bangsberg
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

7.  Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.

Authors:  D L Thomas; J W Shih; H J Alter; D Vlahov; S Cohn; D R Hoover; L Cheung; K E Nelson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

8.  Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown.

Authors:  Inmaculada Castillo; Margarita Pardo; Javier Bartolomé; Nuria Ortiz-Movilla; Elena Rodríguez-Iñigo; Susana de Lucas; Clara Salas; Jose A Jiménez-Heffernan; Arturo Pérez-Mota; Javier Graus; Juan Manuel López-Alcorocho; Vicente Carreño
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

9.  Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.

Authors:  Sarah L George; Jenny Gebhardt; Donna Klinzman; Mathew B Foster; Kevin D Patrick; Warren N Schmidt; Beth Alden; Michael A Pfaller; Jack T Stapleton
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

10.  Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area.

Authors:  Norbert Bräu; Edmund J Bini; Azra Shahidi; Ayse Aytaman; Peiying Xiao; Saray Stancic; Robert Eng; Sheldon T Brown; Fiorenzo Paronetto
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  7 in total

1.  Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission.

Authors:  Ariane Larouche; Geneviève Gaëtan; Nabil El-Bilali; Mathieu Quesnel-Vallières; Steven R Martin; Fernando Alvarez; Naglaa H Shoukry; Hugo Soudeyns
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction.

Authors:  Jyoti Barokar; Allen McCutchan; Reena Deutsch; Bin Tang; Mariana Cherner; Ajay R Bharti
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

Review 3.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 4.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 5.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

6.  Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM).

Authors:  Astrid M Newsum; Ineke G Stolte; Jan Tm van der Meer; Janke Schinkel; Marc van der Valk; Joost W Vanhommerig; Anne Buvé; Mark Danta; Arjan Hogewoning; Maria Prins
Journal:  Euro Surveill       Date:  2017-05-25

7.  Hepatitis C Virus Infection among HIV-Infected Patients Attending Dessie Referral Hospital, Northeastern Ethiopia.

Authors:  Alemu Gedefie; Aderaw Adamu; Ermiyas Alemayehu; Yeshimebet Kassa; Melaku Ashagrie Belete
Journal:  Int J Microbiol       Date:  2021-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.